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Indoxyl Sulphate is Associated with 
Atrial Fibrillation Recurrence after 
Catheter Ablation
Fumi Yamagami1, Kazuko Tajiri  1, Kosuke Doki2, Masayuki Hattori1, Junya Honda  1, 
Satoshi Aita1, Tomohiko Harunari1, Hiro Yamasaki1, Nobuyuki Murakoshi1, Yukio Sekiguchi1, 
Masato Homma2, Naohiko Takahashi3, Kazutaka Aonuma1, Akihiko Nogami1 & Masaki Ieda1
Renal dysfunction results in the accumulation of various uremic toxins, including indoxyl sulphate 
(IS), and is a major risk factor for atrial fibrillation (AF). Experimental studies have demonstrated 
that IS exacerbates atrial remodelling via oxidative stress, inflammation, and fibrosis. However, its 
clinical impact on AF-promoting cardiac remodelling has not been described. Therefore, the purpose 
of this study was to clarify the relationship between basal IS levels and the 1-year outcomes after 
catheter ablation for the treatment of AF. Our prospective observational study included data from 125 
patients with AF who underwent catheter ablation. Over a 1-year follow-up period, AF recurrence was 
identified in 21 patients. The 1-year AF-free survival was significantly lower in patients with high serum 
IS levels (≥0.65 μg/mL) than in those with low IS levels (60.1 ± 10.4% versus 85.2 ± 3.9%, P = 0.007). 
Univariable analysis identified that an IS concentration ≥ 0.65 μg/mL was associated with AF recurrence 
(hazard ratio [HR] = 3.10 [1.26–7.32], P = 0.015), and this association was maintained in multivariate 
analysis (HR = 3.67 [1.13–11.7], P = 0.031). Thus, in patients undergoing AF ablation, serum IS levels at 
baseline independently predict the recurrence of arrhythmia.
Several clinical trials have reported a close association between atrial fibrillation (AF) and chronic kidney disease 
(CKD)1–5. For example, the burden of AF is increased among patients with CKD, and AF itself increases as a func-
tion of CKD severity. The relationship between renal function and AF recurrence after catheter ablation for AF 
was addressed in recent reports6–8. Patients with a lower estimated glomerular filtration rate (eGFR) at baseline 
had a greater risk of recurrence after radiofrequency catheter ablation for AF. Atrial remodelling due to CKD 
was thought to be responsible for the poor outcome after AF ablation in patients with CKD; however, the exact 
mechanism of this association remains to be elucidated.
Indoxyl sulphate (IS) is among the most representative uremic toxins derived from the metabolism of dietary 
protein by the gut microbiota and has been implicated in the pathogenesis of various cardiovascular diseases9–11, 
including AF12. Experimental studies in animal models have shown that IS can exacerbate AF via its effect on 
cardiac fibrosis and inflammation, with enhanced oxidative stress and reduced anti-oxidative defense13,14. These 
effects have been shown to induce arrhythmogenesis in pulmonary veins, sinoatrial nodes, and atria isolated from 
rabbit hearts15. Recently, Aoki et al.16 demonstrated, in a rat model of CKD, that IS increases the inducibility of 
AF, and that circulating levels of IS can be significantly attenuated by using an absorbent of uremic toxins, such 
as AST-120. Thus, it is plausible that IS may contribute to atrial remodelling, although there is limited clinical 
evidence in support of the association between IS and AF.
Therefore, the aim of our study was to investigate the relationship between IS and recurrent AF in patients 
after radiofrequency catheter ablation (RFCA) for AF.
Methods
Study population. This prospective observational study was conducted at the University of Tsukuba 
Hospital, Tsukuba, Japan, between April 2009 and March 2011. We enrolled 125 consecutive patients with 
non-valvular AF scheduled for RFCA for AF. Patients who had hemodynamically significant (moderate-to-se-
vere) valvular disease, thrombus in the left atrium (LA), uncontrolled thyroid dysfunction, pre-procedural 
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significant coronary artery stenosis, a previous myocardial infarction or cardiac surgery in the previous 3 months, 
contraindications to anticoagulant therapy, stage 4 or 5 CKD, or pregnancy were excluded.
All enrolled patients had symptomatic paroxysmal or persistent AF and had not responded to treatment with 
one or more antiarrhythmic drugs. Long-standing persistent AF was defined as any AF episode lasting for longer 
than 1 year. A detailed medical history regarding AF and related cardiovascular and/or systemic conditions was 
obtained from all patients. The CHADS2 score was calculated for each patient based on a point system, as previ-
ously described17. Transthoracic echocardiography was also performed to assess left ventricular function and the 
left atrial volume index (LAVI) before RFCA.
The study was in compliance with the principles outlined in the Declaration of Helsinki and was approved by 
Ethics Committee, University of Tsukuba Hospital. Before ablation, written informed consent was obtained from 
all the patients.
Study endpoint. The endpoint of this study was recurrence of AF or atrial tachycardia after a blanking 
period of 3 months.
Serum IS concentration. Blood samples were collected from patients just before ablation and serum 
was stored at −80 °C. Serum levels of IS and indole-3 acetic acid (IAA) were measured by reversed-phase 
high-performance liquid chromatography using a conventional octadecylsilyl silica column and a fluorescence 
detector, according to a previously described method, with minor modifications18. The coefficients of variation 
for intra-day and inter-day assays were <3%.
Classification of CKD. Classification of the CKD stage was determined using the eGFR, calculated at base-
line. The eGFR was calculated using the estimation equation for Japanese patients with CKD19. This equation 
calculates the eGFR from serum creatinine, adjusted for age and sex, using the following formula: (eGFR [mL/
min/1.73 m2] = 194 × age−0.287 × serum creatinine−1.094 × [0.739 for women]). The study population was divided 
into three subgroups: patients with an eGFR ≥ 90 mL/min/1.73 m2 (CKD stage 1), patients with an eGFR between 
60 and 89.9 mL/min/1.73 m2 (CKD stage 2), and patients with an eGFR between 30 and 59.9 mL/min/1.73 m2 
(CKD stage 3). The creatinine clearance (CrCl) was evaluated using the Cockcroft–Gault formula: CrCl (mL/
min) = ([140 - age] × body weight [kg] × [0.85 if female])/(72 × serum creatinine [mg/dL]).
Catheter ablation. Procedures were performed under general anaesthesia, aiming at an anticoagulation 
time of 300 s. An irrigated-tip catheter was used to deliver radiofrequency energy in all patients. A circular lasso 
catheter was used to confirm the pulmonary vein (PV) and to map the LA area. After trans-septal puncture, PV 
isolation (PVI) was performed. After PVI, a bidirectional block was systematically obtained in all veins. In the 
case of persistent AF, complete electrical isolation of the PVs was confirmed after restoration of a sinus rhythm. 
If the AF was sustained or recurred despite the internal cardioversion after PVI, a stepwise approach was used, 
including linear ablation of the LA roof, superior vena cava isolation, and/or ablation of complex fractionated 
atrial electrograms.
Follow-up. Follow-up was performed at 1, 3, 6, and 12 months, or earlier if a patient developed symp-
toms consistent with recurrent AF. The average follow-up period was 11.7 months (range, 3.2 to 12 months). 
Recurrence was defined as any evidence of an episode of atrial arrhythmia lasting for more than 30 s after a 
3-month blanking period.
Statistical analysis. Analyses were performed using JMP software (version 10). Values are reported as the 
mean ± standard deviation (SD) for continuous variables, and proportions for categorical variables. The optimal 
cut-off point was determined by the maximum Youden index based on receiver operating characteristic (ROC) 
curve analysis, and areas under the ROC curve (AUCs) were calculated. The association between serum levels of 
IS or IAA and other factors was evaluated using Pearson’s correlation coefficients. Differences between continu-
ous values were assessed using an unpaired, two-tailed, t-test for normally distributed continuous variables, and 
a Mann–Whitney test for skewed variables. The chi-square statistic was used for testing relationships between 
categorical variables. The association between baseline variables and AF recurrence was evaluated using univar-
iate and multivariate Cox proportional hazards analysis. AF-free survival curves were analysed according to the 
Kaplan–Meier method and compared by the log-rank test. A P-value < 0.05 was considered significant.
Results
Study population. Of the 125 consecutive patients with AF enrolled, 20 were excluded from the analysis 
due to missing pre-echocardiographic data (5 patients) and because of a lack of follow-up (15 patients). Relevant 
data of the remaining 105 patients (83.8% men, mean age: 60.0 ± 10.8 years) included in the analysis are reported 
in Table 1. Over the 1-year follow-up after ablation, 21 (20.0%) patients developed AF recurrence (AF in 16, 
uncommon atrial flutter in 1, and atrial tachycardia in 4 patients). There were no significant differences in base-
line IS and IAA levels between patients who developed AF-recurrence and those who did not (IS, 0.51 ± 0.33 vs 
0.43 ± 0.31 μg/mL, P = 0.27; IAA, 0.14 ± 0.05 vs 0.16 ± 0.10 μg/mL, P = 0.31, respectively). After calculating the 
maximum Youden index (sensitivity + specificity − 1) and the AUC, the optimal cut-off values of serum levels of 
IS and IAA were found to be 0.65 μg/mL and 0.17 μg/mL, respectively (Table 2).
Relationship of serum IS levels with renal function and age. Serum IS levels were significantly 
increased in patients with CKD stage 3 (Fig. 1). However, the correlations of serum IS levels with eGFR 
(r = −0.295, P = 0.002) and CrCl (r = −0.263, P = 0.007) were weak (Fig. 2a,b). IS levels were also weakly corre-
lated with age (r = 0.253, P = 0.009; Fig. 2c).
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IAA is also a uremic toxin and belongs to the family of indolic uremic solutes, such as IS. Serum levels of IAA 
were positively correlated with those of IS (r = 0.443, P < 0.001; Supplementary Fig. S1). In this cohort, unlike 
IS, IAA levels did not differ statistically significantly among patients with CKD stage 1, 2, and 3 (Supplementary 
Fig. S2). IAA levels were weakly correlated with eGFR (r = −0.255, P = 0.009), but not with CrCl (r = −0.102, 
P = 0.30) or age (r = −0.029, P = 0.77) (Supplementary Fig. S3).
Demographic and clinical characteristics of patients with high IS levels. Among the 105 patients 
in our study group, 23 patients (21.9%) were categorized into the high IS (≥0.65 μg/mL) and 82 patients (78.1%) 
into the low IS group (<0.65 μg/mL; Table 1) according to the optimal cut-off value. There were no significant 
differences in sex or age between the two groups. The duration after diagnosis of AF was significantly longer 
in the high IS group (P = 0.010). Patients with high IS levels had lower eGFR (P = 0.019), an increased LAVI 
(P = 0.012), an elevated BNP (P = 0.042), and were more likely to have been treated with beta-blockers before 
ablation (P = 0.003). After ablation, the proportion of patients taking class III anti-arrhythmic drugs (AAD) was 
significantly higher in the high-IS group than in the low-IS group (P = 0.004, Supplementary Table S1).
All (n = 105)
IS ≥ 0.65 μg/mL 
(n = 23)
IS < 0.65 μg/mL 
(n = 82) P-value
Age (years) 60.0 ± 10.8 62.9 ± 11.3 59.2 ± 10.6 0.14
Male sex 88 (83.8) 20 (87.0) 68 (82.9) 0.64
Body mass index (kg/m2) 23.6 ± 2.9 23.7 ± 3.2 23.6 ± 2.9 0.94
Paroxysmal AF 69 (65.7) 14 (60.9) 55 (67.1) 0.58
Long-standing AF 19 (19.1) 7 (30.4) 12 (14.6) 0.082
Duration of AF history (years) 5.5 ± 5.7 8.4 ± 6.9 4.8 ± 5.2 0.010
Medication
ACEIs/ARBs 44 (41.9) 10 (43.5) 34 (41.5) 0.86
Statins 33 (31.4) 5 (21.7) 28 (34.2) 0.26
Beta-blockers 58 (55.2) 19 (82.6) 39 (47.6) 0.003
Class I AADs 59 (56.2) 12 (52.2) 47 (57.3) 0.66
Class III AADs 34 (32.4) 10 (43.5) 24 (29.3) 0.20
Class IV AADs 16 (15.2) 2 (8.7) 14 (17.1) 0.32
Hypertension 52 (49.5) 13 (56.5) 39 (47.6) 0.45
Diabetes mellitus 14 (13.3) 3 (13.0) 11 (13.4) 0.96
Dyslipidaemia 48 (45.7) 9 (39.1) 39 (47.6) 0.47
CHADS2 score 0.81 ± 0.84 1.04 ± 0.88 0.74 ± 0.83 0.13
Echocardiogram parameters
LVEF (%) 65.2 ± 11.2 66.3 ± 12.4 64.9 ± 10.9 0.62
LAVI (mL/m2) 36.3 ± 18.3 44.7 ± 22.0 33.8 ± 16.4 0.012
eGFR (mL/min/1.73 m2) 76.1 ± 18.5 68.2 ± 20.9 78.4 ± 17.3 0.019
CKD stage 0.021
Stage 1 19 (18.1) 4 (17.4) 15 (18.3)
Stage 2 69 (65.7) 11 (47.8) 58 (70.7)
Stage 3 17 (16.2) 8 (34.8) 9 (11.0)
BNP (pg/mL) 78.9 ± 91.6 114.1 ± 111.7 69.5 ± 83.8 0.042
CRP (mg/mL) 0.097 ± 0.102 0.114 ± 0.111 0.092 ± 0.099 0.34
IS (μg/mL) 0.45 ± 0.31 0.93 ± 0.25 0.31 ± 0.15  < 0.001
IAA (μg/mL) 0.16 ± 0.10 0.18 ± 0.07 0.15 ± 0.10 0.097
Table 1. Baseline characteristics. Values are given as mean ± SD or number (%). AAD, anti-arrhythmic drug; 
AF, atrial fibrillation; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor antagonist; 
BNP, B-type natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IAA, 
indole-3 acetic acid; IS, indoxyl sulphate; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction.
Median 
value Range AUC
Cut-off 
value
IS (μg/mL) 0.36 0–1.74 0.576 0.65
IAA (μg/mL) 0.13 0.04–0.56 0.522 0.17
Table 2. Optimal cut-off point based on AF recurrence. AF, atrial fibrillation; AUC; area under the curve, IAA, 
indole-3 acetic acid; IS, indoxyl sulphate.
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AF-free survival. The 1-year AF-free survival was significantly lower in patients with a high serum IS level 
than in those with a low IS level (60.1 ± 10.4% vs 85.2 ± 3.9%, P = 0.007; Fig. 3a). However, the 1-year AF-free 
survival did not differ (P = 0.25) between patients with high IAA levels (85.9 ± 5.8%) and those with low IAA 
levels (76.6 ± 5.1%) (Supplementary Fig. S4).
Overall, in our study group, 76 patients (72.4%) underwent a first AF ablation, with the remaining 29 (27.6%) 
undergoing a repeat AF ablation. Among the 29 patients with recurrent AF, recovery of electrical conduction 
between the PVs and the LA was identified in 26 patients (89.7%). Among patients who underwent a first AF 
ablation, the 1-year estimates of AF-free survival were 47.6 ± 13.8% for those with a high serum IS level and 
85.5 ± 4.5% for those with a low IS level (P = 0.003; Fig. 3b). In contrast, among patients who underwent a repeat 
AF ablation (Fig. 3c), the 1-year AF-free survival did not significantly differ (P = 0.58) between patients with high 
IS levels (77.9 ± 13.9%) and those with low IS levels (84.2 ± 8.4%).
Predictive value of IS in AF recurrence. On univariate analysis, an IS level ≥ 0.65 μg/mL was associated 
with an increased risk of AF recurrence (hazard ratio [HR]: 3.10, 95% CI: 1.26–7.32; P = 0.015; Table 3). After 
adjustment for age and sex, an IS level ≥ 0.65 μg/mL remained associated with increased risk of AF recurrence 
(HR: 3.76, 95% CI: 1.52–9.03; P = 0.005; Table 3). In the multivariate Cox proportional hazard model, adjusted for 
age, sex, duration after AF diagnosis, beta-blocker use before ablation, LAVI, BNP, Class III AAD use after abla-
tion, as well as eGFR or CKD stage, an IS level ≥ 0.65 μg/mL remained as an independent predictor of AF recur-
rence (HR 3.60, 95% CI: 1.12–11.0, P = 0.032; and HR 3.67, 95% CI: 1.13–11.7, P = 0.031, respectively; Table 3).
Discussion
In this prospective observational study, we identified high IS levels as a strong and independent predictor of AF 
recurrence in patients undergoing successful catheter ablation. To the best of our knowledge, this association of 
uremic toxins with the outcomes of AF ablation has not been described previously.
The high AF recurrence rate after ablation in patients with CKD is indicative of a possible involvement of 
uremic toxins in AF pathogenesis. However, no clinical studies to date have demonstrated the involvement of 
uremic toxins in AF recurrence. Here, we showed that patients with a higher IS levels exhibited a higher rate of 
AF recurrence after ablation, with serum IS being a significant predictor of AF recurrence, even after adjustment 
for eGFR or the stage of CKD. Thus, it seems that IS has a predictive role in AF recurrence.
In recent years, increasing attention has been paid to the relationship between IS and cardiovascular diseases 
among patients with CKD. Barreto et al.20 reported that a higher serum level of IS was associated with an increased 
overall mortality and cardiovascular-specific mortality among patients with CKD. Furthermore, Lin et al.21  
indicated that IS was a valuable marker in predicting cardiovascular events in patients with advanced CKD. Other 
researchers have reported association of a high IS level with increased risk of LV diastolic dysfunction22,23.
In our study cohort, the IS concentration correlated poorly with eGFR (Fig. 1), which was consistent with the 
findings from other groups24,25. IS is a gut-derived uremic toxin and factors other than the GFR, such as renal 
tubular secretion, diet and intestinal absorption, and gut microbiota metabolism, may affect IS concentration26.
Recent animal studies have revealed the causative role of IS in promoting AF remodelling. Chen et al.15 reported 
that IS induced the occurrence of delayed after-depolarizations and burst firing in PVs isolated from rabbits. They 
also showed that IS-treated PV cardiomyocytes had a larger Ca2+ leak than control PV cardiomyocytes15. Aoki et 
al.16 showed that, in rat models of renal failure induced by 5/6 nephrectomy, administration of AST-120, which is 
commonly used in clinical practice as an absorbent of uremic toxins, attenuated oxidative stress, inflammation, and 
fibrosis in the LA, and decreased AF inducibility in vivo. In cultured atrial fibroblasts, incubation with IS upregulated 
the expression of oxidative stress markers NOX2/NOX4 and malondialdehyde, along with an increase in inflam-
matory and profibrotic signalling molecules, such as monocyte chemoattractant protein 1 (MCP-1), transforming 
growth factor β1 (TGF-β1), α-smooth muscle actin (α-SMA), and collagen I16. These results indicate a direct effect 
of IS on the progression of the AF substrate. Therefore, IS may become a novel therapeutic target for AF.
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Figure 1. Serum levels of IS are increased in patients with reduced renal function. CKD, chronic kidney 
disease; IS, indoxyl sulphate.
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The prevalence of AF among a large population of patients with CKD was found to be 2- to 3-fold higher than 
that in the general population27,28. Moreover, the prevalence of AF among dialysis patients has been reported to 
range between 7% and 27%29–32, as compared to 0.4% to 1.0% in the general population33, indicating that hae-
modialysis may not eliminate the risk of AF in CKD. Therefore, non-dialyzable uremic factors were considered 
responsible for AF-promoting remodelling. IS is a poorly dialyzable uremic toxin due to its high protein binding. 
Even after haemodialysis, the serum IS levels still remain high34. Therefore, accumulating IS may directly contrib-
ute to atrial remodelling in patients with CKD.
b
a
CrCl (mL/min)
Se
ru
m
 IS
 (
g/
m
L)
20050 100 150
P = 0.007
r = -0.263
0
1.8
1.5
1.2
0.9
0.6
0.3
0
P = 0.002
r = -0.294
Se
ru
m
 IS
 (
g/
m
L)
20
1.8
1.5
1.2
0.9
0.6
0.3
0
40 60 80 100 120 140
eGFR (mL/min/1.73m2)
Age (years old)
Se
ru
m
 IS
 (
g/
m
L)
9040 60 80
P = 0.009
r = 0.252
20
1.8
1.5
1.2
0.9
0.6
0.3
0
30 50 70
c
Figure 2. Correlations between serum levels of IS and eGFR (a), CrCl (b), or age (c). CrCl, creatinine clearance; 
eGFR, estimated glomerular filtration rate; IS, indoxyl sulphate.
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Limitations. The study had some limitations. First, compared to patients in the low IS level group, the duration 
after AF diagnosis had been longer in the cohort of patients with high IS levels; this group also had a greater prevalence 
of beta-blocker use, increased LAVI, and worse renal function, which would be sources of possible residual confound-
ing factors. Furthermore, our study evaluated a heterogeneous population, including patients with paroxysmal as well 
as persistent AF. Because of the small sample size, no separate analysis was possible between these different groups. 
Consequently, we cannot rule out different biomarker patterns between these two entities of AF. Second, the diag-
nosis of AF recurrence was based on the occurrence of symptoms and periodic and occasional ECG recordings and 
Holter ECG findings. Therefore, some patients with asymptomatic AF recurrence might have been missed. Third, our 
cohort included individuals who underwent AF ablation at our institution between 2009 and 2011. During that period, 
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Figure 3. Impact of IS levels on the recurrence of AF after catheter ablation. The AF-free survival rates are 
shown for the whole cohort (a), patients undergoing a first AF ablation (b), and patients undergoing a repeat 
AF ablation (c) according to IS levels. The numbers at the bottom of the graph indicates the number of ‘at risk’ 
patients in each follow-up month. AF, atrial fibrillation; IS, indoxyl sulphate.
www.nature.com/scientificreports/
7SCiEnTiFiC RepoRTS |         (2018) 8:17276  | DOI:10.1038/s41598-018-35226-5
advanced technologies that are widely used today, including the contact force-sensing catheter and balloon ablation, 
were not approved for use in Japan. These newer technologies have been reported to increase the durability of PV isola-
tion and reduce AF recurrence35,36. Further studies may be needed to determine whether high IS levels can predict AF 
recurrence in the current setting of AF ablation. Fourth, patients who had haemodynamically significant valvular heart 
disease or stage 4 or 5 CKD, or received dialysis were excluded from this study. Further studies are needed to determine 
whether high IS levels can also predict AF recurrence in those patients. Fifth, it has been reported that there were some 
diurnal and inter-day variations in the circulating IS concentrations37, and dietary protein intake affected the IS concen-
trations38. However, in this study, blood samples were collected at a single time point, but were not collected at the same 
time of the day for all patients, and were not standardized with respect to food intake. Finally, this study was performed 
in a single centre with a relatively small sample size and a short follow-up period. Therefore, further studies with more 
patients and a longer follow-up period may be needed to confirm our study results.
Conclusion
Serum IS levels are associated with recurrence of AF after catheter ablation. Therefore, the IS level should be con-
sidered in the prediction of recurrence after ablation.
Data Availability
The datasets generated and/or analysed during the current study are available from the corresponding author 
upon reasonable request.
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